Potential Applications of 68Ga-PSMA-11 PET/CT in the Evaluation of Salivary Gland Uptake Function: Preliminary Observations and Comparison with 99mTcO4− Salivary Gland Scintigraphy
Table 1
Patient data and analysis of the uptake characteristics of and 68Ga-PSMA-11 in all 15 patients.
Patient no.
Sex
Age (Y)
History
Abnormal uptake of in PG or SM
Abnormal uptake of 68Ga-PSMA-11 in PG or SM
Additional findings from 68Ga-PSMA-11 PET/CT
1
F
55
Sjogren’s syndrome
Lt. PG
Lt. PG
Rt. LG, T
2
F
67
Sjogren’s syndrome
Rt. SM, Lt. SM
Rt. SM, Lt. SM
Rt. LG, Lt. LG
3
M
71
Sjogren’s syndrome
Rt. PG, Lt. PG
Rt. PG, Lt. PG
Rt. LG, Lt. LG
4
M
70
Sjogren’s syndrome
Rt. SM
Rt. SM
—
5
M
64
NPC after radiotherapy and chemotherapy
Rt. SM, Lt. SM
Rt. SM, Lt. SM
Rt. SM
6
M
64
Vocal cord cancer after radiotherapy and chemotherapy
Lt. PG, Lt. SM
Lt. PG, Lt. SM
—
7
F
41
NPC after radiotherapy and chemotherapy
Lt. PG
Lt. PG
—
8
F
66
NPC after radiotherapy and chemotherapy
Rt. SM
Rt. SM
—
9
M
75
Papillary carcinoma of the jaw after radiotherapy and chemotherapy
N
N
—
10
M
72
Vocal cord cancer after radiotherapy and chemotherapy
N
N
—
11
M
46
NPC after radiotherapy and chemotherapy
N
N
—
12
M
19
EMP of nasal cavity after radiotherapy and chemotherapy
N
N
—
13
M
50
NPC after radiotherapy and chemotherapy
Rt. SM
N
—
14
F
43
NPC after radiotherapy and chemotherapy
Lt. PG
N
—
15
M
50
Postoperative treatment of left parotid acinar cell carcinoma
N
Lt. PG
Lt. PG
NPC = nasopharyngeal carcinoma; EMP = extramedullary plasmacytoma; N = negative; LG = lacrimal gland; PG = parotid gland; SM = submandibular gland; T = Thyroid. “—” means no relevant data.
